載入中
HKSEHealthcareBiotechnology
最新資料
HK$0.30
+HK$0.01 · +3.45%
China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of medicinal products, serving both the People's Republic of China and international territories. The firm develops and markets prescription medications addressing a diverse array of medical conditions, including oncological and hematological diseases, gastrointestinal disorders, central nervous system afflictions, and respiratory illnesses, among other therapeutic fields. In addition to these specialized drugs, it also produces and distributes its proprietary "NT" branded products and generic formulations. Furthermore, the group extends its offerings to include marketing and promotional assistance for suppliers, alongside providing logistics and consulting solutions. Established in 1995, the company maintains its corporate headquarters in Suzhou, People's Republic of China.
最新資料
HK$0.30
+HK$0.01 · +3.45%
盤中時間採用HKT。市場資料可能有所延遲。
China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of medicinal products, serving both the People's Republic of China and international territories. The firm develops and markets prescription medications addressing a diverse array of medical conditions, including oncological and hematological diseases, gastrointestinal disorders, central nervous system afflictions, and respiratory illnesses, among other therapeutic fields. In addition to these specialized drugs, it also produces and distributes its proprietary "NT" branded products and generic formulations. Furthermore, the group extends its offerings to include marketing and promotional assistance for suppliers, alongside providing logistics and consulting solutions. Established in 1995, the company maintains its corporate headquarters in Suzhou, People's Republic of China.
日內區間
目前HK$0.30
52週區間
目前HK$0.30
盤中時間採用HKT。市場資料可能有所延遲。
China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of medicinal products, serving both the People's Republic of China and international territories. The firm develops and markets prescription medications addressing a diverse array of medical conditions, including oncological and hematological diseases, gastrointestinal disorders, central nervous system afflictions, and respiratory illnesses, among other therapeutic fields. In addition to these specialized drugs, it also produces and distributes its proprietary "NT" branded products and generic formulations. Furthermore, the group extends its offerings to include marketing and promotional assistance for suppliers, alongside providing logistics and consulting solutions. Established in 1995, the company maintains its corporate headquarters in Suzhou, People's Republic of China.
日內區間
目前HK$0.30
52週區間
目前HK$0.30
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CNY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2415.8萬 CNY | 3796萬 CNY | 736.6萬 CNY | 2.07億 CNY | 2.27億 CNY |
| 銷貨成本 | 1454.8萬 CNY | 3270萬 CNY | — | 8180.6萬 CNY | 8124萬 CNY |
| 毛利 | 961萬 CNY | 526萬 CNY | 736.6萬 CNY | 1.25億 CNY | 1.45億 CNY |
| 研究與開發 | — | — | — | 376.2萬 CNY | 595.9萬 CNY |
| 銷售、一般及管理費用 | 2197.4萬 CNY | 1848.6萬 CNY | 5876.2萬 CNY | 2262.2萬 CNY | 2.31億 CNY |
| 營業費用 | 2197.4萬 CNY | 1848.6萬 CNY | 6357.4萬 CNY | 2641.7萬 CNY | 2.44億 CNY |
| 利息收入 | 6818 CNY | 1.1萬 CNY | 9000 CNY | 4萬 CNY | 23.9萬 CNY |
| 利息支出 | 2711.95萬 CNY | 3154.4萬 CNY | 2881.8萬 CNY | 3936.5萬 CNY | 8872.7萬 CNY |
| 折舊和攤銷 | 64.4萬 CNY | 66萬 CNY | 588.1萬 CNY | 2107萬 CNY | 4224.9萬 CNY |
| 營業利益 | −1236.4萬 CNY | −1322.6萬 CNY | −5620.8萬 CNY | −2654.2萬 CNY | −9943.3萬 CNY |
| 淨利 | −2604.1萬 CNY | −5335.7萬 CNY | −1.44億 CNY | −6640.5萬 CNY | −1.5億 CNY |
公司資料更新於 2026年10月18日。
近期已公布業績
近期已公布業績
年度分割調整後的每股現金分配。
HK$0.035
2018年（完整年度）+250.0% 自從 2016
HK$0.01
2,016
HK$0.025
2,017
HK$0.035
2,018
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2018年7月10日 | HK$0.035Annual | 2018年7月11日 | 2018年8月2日 |
股息 | 2017年6月8日 | HK$0.025Annual | 2017年6月9日 | 2017年7月3日 |
股息 | 2016年5月31日 | HK$0.01Annual | 2016年6月1日 | 2016年6月15日 |
除息 2018年7月10日
HK$0.035
Annual
2018年7月11日登記 · 支付日 2018年8月2日
除息 2017年6月8日
HK$0.025
Annual
2017年6月9日登記 · 支付日 2017年7月3日
除息 2016年5月31日
HK$0.01
Annual
2016年6月1日登記 · 支付日 2016年6月15日
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
